Abstract
In a double-blind placebo-controlled prospective clinical trial we studied the efficacy and safety of the benzodiazepine antagonist, flumazenil. In 23 patients admitted to the Intensive Care Unit with coma due to overdose with benzodiazepines or other sedatives, flumazenil i.v. (up to 2mg or placebo) was given. In 13 patients given flumazenil the Glasgow Coma Scale (GCS) increased significantly from 4.9 to 7.8 (p<0.05). Six of these 13 patients, including mainly benzodiazepine mono-intoxications, needed only one series of injections (up to 1.0 mg flumazenil); the GCS increased thereby from 4.5 to 10.7 within a maximum of 5 min (p<0.01). In the remaining 7 patients, needing two series of injections of flumazenil (up to 2.0 mg), GCS did not rise significantly and coma was related to intoxications with nonbenzodiazepine sedatives, flunitrazepam and in one patient, encephalitis. In the 10 patients receiving placebo, the GCS did not change. A significant increase in the GCS from 5.5 to 10.8 (p<0.001) was, however, observed when flumazenil (up to 1.0 mg) was given after placebo. In patients with EEG monitoring the changes in waveform pattern paralleled the clinical response. Effects could be detected within 1–2min after flumazenil injection and lasted up to 45min. There were no adverse reactions or benzodiazepine withdrawal symptoms. We conclude that flumazenil is an effective and safe drug in the treatment of benzodiazepine overdose. The use of flumazenil is of diagnostic value in mixed-drug intoxications or coma of unknown origin and is of therapeutic importance for reversal of benzodiazepine intoxications.
Similar content being viewed by others
References
Bonetti EP, Pieri L, Cumin R, Schaffner R, Pieri M, Gamzu ER, Müller RKM, Haefely W (1982) Benzodiazepine antagonist Ro 15-1788: Neurological and behavioral effects. Psychopharmacology 78:8–18
Lauven PM, Stoeckel H, Schwilden H, Arendt R, Greenblatt DJ, Schüttler J (1982) Application of a benzodiazepine antagonist (Ro 15-1788) under steady-state conditions of midazolam. Anesthesiology 57:A325
Polc P, Bonetti EP, Schaffner R, Haefely W (1982) A threestate model of the benzodiazepine receptor explains the interactions between the benzodiazepine antagonist Ro 15-1788, benzodiazepine tranquilizers, ß-carbolines, and phenobarbitone. Naunyn Schmiedebergs Arch Pharmacol 321:260–264
Louis M, Forster A, Suter PM, Gemperle M (1984) Clinical and hemodynamic effects of a specific benzodiazepine antagonist (Ro 15-1788) after open heart surgery. Anaesthesiology 61 [Suppl]:A61
Alon E, Baitella L, Hossli G (1985) Ro 15-1788 in reversing midazolam used for laparoscopy (preliminary communications). Acta Anaesthesiol Scand [Suppl]:80, 89
Geller E, Niv D, Matzkin C, Silbiger A, Nevo I, Cohen F, Braf Z (1985) The antagonism of midazolam sedation by Ro 15-1788 in postoperative patients. Anesthesiology 63 [Suppl]:A369
Roncari G, Ziegler WH, Guentert TW (1986) Pharmacokinetics of the new benzodiazepine antagonist Ro 15-1788 in man following intravenous and oral administration. Br J Clin Pharmacol 22:421–428
Ziegler WH, Schalch E (1983) Antagonism of benzodiazepine-induced sedation in man. In: Koella W (ed) 6th Europ congress in sleep research, Zürich. Karger, Basel, 1983, pp 427–429
Forster A, Rouiller M, Morel D, Gemperle M (1983) Doubleblind randomized study evaluating a specific benzodiazepine antagonist. Anesthesiology 59:A375
Klotz U, Ziegler G, Reimann IW (1984) Pharmacokinetics of the selective benzodiazepine antagonist Ro 15-1788 in man. Eur J Clin Pharmacol 27:115–117
Hofer P, Scollo-Lavizzari G (1985) Benzodiazepine antagonist Ro 15-1788 in self poisoning. Diagnostic and therapeutic use. Arch Intern Med 145:663–664
Lheureux P, Askenasi R (1986) Benzodiazepine antagonist Ro 15-1788 in self-poisoning. Arch Intern Med 146:1241
Geller E, Niv D, Silbiger A, Halpern P, Leykin Y, Rudick V, Sorkin P (1986) Ro 15-1788, a benzodiazepine antagonist in the treatment of 34 intoxicated patients. Anesthesiology 63 [Suppl]:A157
Geller E, Niv D, Rudick V, Vidne B (1984) The use of Ro 15-1788: A benzodiazepine antagonist Ro the diagnosis and treatment of benzodiazepine overdose. Anesthesiology 61 [Suppl]:A135
Kleiberger G, Grimm G, Laggner A, Druml W, Lenz K, Schneeweiss B (1985) Weaning patients from mechanical ventilation by benzodiazepine antagonist Ro 15-1788. Lancet II:268–269
Teasdale G, Jennett B (1974) Assessment of coma and impaired consciousness. A practical scale. Lancet II:81–83
Silverman D (1963) Retrospective study of the EEG in coma. Electroenceph Clin Neurophysiol 15:486–503
Greenblatt DJ, Shader R, Abernethy DR (1983) Drug therapy. Current status of benzodiazepines (second of two parts). N Engl J Med 309:410–416
Meier PJ, Ziegler WH, Neftel K (1988) Benzodiazepine-Praxis und Probleme über Anwendung. Schweiz Med Wochenschr 118:381–392
Baird ES, Hailey DM (1972) Delayed recovery from a sedative; correlation of the plasma levels of diazepam with clinical effects after oral and intravenous administration. Br J Anaesth 44:803
Rapolt HJ, Follath F, Scollo-Lavizzari G, Kehl O, Ritz R (1984) Verlängertes Koma durch Sedation mit Diazepam bei beatmeten Patienten. Dtsch Med Wochenschr 109:340–344
Teasdale G, Murray G, Parker L, Jennett B (1979) Adding up the Glasgow Coma Score. Acta Neurochir [Suppl] 28:13–16
Geller E, Niv D, Silbinger A, Halpern P, Leykin Y, Rudick V, Sorkin P (1985) Ro 15-1788: a benzodiazepine antagonist in the treatment of 34 intoxicated patients. Anesthesiology 63:A157
Zuber M, Elsasser S, Ritz R, Scollo-Lavizzari G (1988) Flumazenil (Anexate®) in severe intoxication with carbamazepine (Tegretol®). Eur Neurol 28:161–163
Hruby K, Prischl F, Donner A, Grimm G, Smetana R (1988) Value of flumazenil in benzodiazepine self-poisoning. Eur Anaesthesiol [Suppl] 2:309–313
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ritz, R., Zuber, M., Elsasser, S. et al. Use of flumazenil in intoxicated patients with coma. Intensive Care Med 16, 242–247 (1990). https://doi.org/10.1007/BF01705159
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01705159